Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Address: Fürj u. 2. , Budapest, H-1124 Budapest,Hungary
Tel: +36 1 381 0765
Web: http://www.hyd.hu/
HYD LLC. for Cancer Research and Drug Development was established for the research, development and worldwide marketing of pharmaceutical and consumer products based on the proprietary procedure, deuterium depletion, primarily for the prevention and treatment of various kinds of cancer and for exploration of new indication fields for the application of deuterium-depleted water (DDW). Different applications of deuterium depletion are protected by international patents.
In the early nineties, Hungarian molecular biologist, Gábor Somlyai, PhD recognized that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of his research carried out with deuterium-depleted water (DDW) was that tumor cells proved to be extremely sensitive to the withdrawal of deuterium (D). Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and according to the latest results it can also influence other physiological processes like glucose metabolism.
Recently, pharmacological industry started to develop and commercialize deuterium-containing medicines. Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence efficacy and side effect profiles of drugs.
HYD’s approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer and other (e.g. metabolic) diseases.
HYD LLC. is marketing and distributing several products with decreased deuterium content in food and medicinal product categories. For human consumption Preventa® deuterium-depleted carbonated drinking water brand is available with different D-contents. Considering the D concentration of natural waters (140-150 ppm at our latitude), Preventa® products’ deuterium concentration varies between 125 and 45 ppm as it is indicated on the label. The products are mainly targeted on tumorous patients under conventional treatments or in remission and health-conscious consumers mostly in the age group over 40. It is made of deuterium-depleted water, natural mineral water and carbon dioxide. Preventa® is a registered trademark of HYD LLC.
VETERA-DDW-25® is medicinal preparation for veterinary use for the adjuvant therapy of neoplastic diseases of household pets. This first deuterium-depleted drug was registered in 1999. The active agent is deuterium-depleted water (DDW; 25 ppm D). Vetera-DDW-25® is mostly applied to dogs and cats suffering from cancer.
Several editions of the book „Defeating cancer!” written by Gábor Somlyai PhD are available in different languages and can be ordered from the Hungarian and foreign publishers.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Dr. Zsuzsanna Fürst, President of the Ethics Committee for Clinical Pharmacology, elaborates on the role and activities of the ethics committee, shares her insights on structural framework of the application…
Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of…
Irisz Lippai-Nagy, CEO of AmCham Hungary, shares insights on the drivers contributing to economic growth in Hungary, recent policies and reforms, the role of the association, and policy recommendations to…
Oliver Strommer, newly appointed executive director of the British Chamber of Commerce in Hungary (BCCH), introduces the Chamber and its refocused aim of becoming a more dynamic player in business…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to…
Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in…
Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that…
See our Cookie Privacy Policy Here